Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Top Cited Papers
Open Access
- 11 July 2024
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , 7-17
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Design and characterization of a surfactant‐conjugated, long‐acting, balanced GLP‐1/glucagon receptor dual agonistPeptide Science, 2021
- Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASHHepatology, 2020
- The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASHHepatology, 2019
- How bariatric surgery affects liver volume and fat density in NAFLD patientsSurgical Endoscopy, 2017
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Serum Alanine Aminotransferase as a Biomarker of Treatment Response in Nonalcoholic SteatohepatitisClinical Gastroenterology and Hepatology, 2014
- Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodentsPeptide Science, 2012
- Endpoints and clinical trial design for nonalcoholic steatohepatitisHepatology, 2011
- Relative quantitative analysis of glucagon receptor mRNA in rat tissuesMolecular and Cellular Endocrinology, 1994
- The role of glucagon in the regulation of plasma lipidsMetabolism, 1979